Download CISTIPROST tablets "The herbal remedy to help maintain the

CISTIPROST
tablets
"The herbal remedy to help maintain
the physiological function of the prostate and bladder "
FORMULATION PROTECTED BY PATENT
Brief information
The Cistiprost is a nutraceutical made with plant extracts titrated and selected according to
them specific and overt activities and associated to provide with a synergy of action, a
valid protection for prostate function and for irritations and inflammation of the bladder,
which are often attributable to a pathological condition of the prostate.
The Cistiprost represents a real novelty for the completeness of its formulation, synergism,
purity, stability of its components, some of which are covered by worldwide patent for the
extraction method.
All components in Cistiprost have been and continue to be studied and used by leading
international research institutes (see bibliography).
Observations on the pathology of prostatic hypertrophy
The infectious and metabolic problems born by the prostate gland are a frequent cause of
urological consultation.
Often the prostate gland disorders, classified as benign prostatic hyperplasia (BPH) and
prostate cancer, are often connected with aging as well as causes of infectious and
mechanical.
Alterations in the prostate microenvironment, due to events associated with aging and
senescence stromal and / or bacterial events, obstructive, mechanical (eg, cycling and
horse riding) are causes that contribute to the injury of contributing to diseases of this
organ.
The muscle fibers and fibroblasts of the prostate may manifest more in old age, alterations
at the molecular level due to inflammatory stimuli, the basic factor of prostate disease.
During the course of inflammatory diseases has been noted, in fact, that IL-8 stimulates
the growth of the apparatus prostate and increases the detection of T-lymphocytes,
macrophages and cytokines: alterations that occur even during the Benign Prostatic
Hyperplasia. In this regard, the components of the Cistiprost intervene specifically to the
various agents involved in the development of inflammatory disease, prostatic
hypertrophy.
The risk of BPH is increased by the concomitant presence of metabolic syndrome: the
increase in prostate volume is mainly linked to hypertension, obesity and diabetes. This
can be explained considering that hyperinsulinemia is connected with an increase in
sympathetic activity that leads to an activation of the α - receptor, present on the prostate
tissue and on the neck of the bladder, and thus contributes to the symptoms.
Furthermore hypertension appears to be an important factor that increases the incidence
of hematuria in patients with BPH.
In most cases, whatever the exact nature of the complaint or the predominant component
(infectious, inflammatory, obstructive pulmonary disease, etc..), the patient has a set of
symptoms broadly comparable with signs prevalent in lower urinary and sexual.
tract.
In recent years this symptom, present in varying degrees in all benign prostate disease,
has been described as LUTS (Lower Urinary Tract Symptoms) and is characterized by
disturbances such as urinary visuria, urgency, nocturia, dysuria, poor stream, incomplete
emptying. These diseases also lead to sexual disorders (painful ejaculation, azoospermia,
etc..), but the main symptom of all is the pelvic pain.
The presence of chronic inflammation may be the bridge between chronic prostatitis and
benign prostatic hyperplasia with fibromuscular proliferation typical of BPH.
Based on numerous histopathological, pharmacological and morphofunctional findings we
can assume the existence of a pathogenic condition (inflammatory syndrome) common in
prostatitis, benign prostatic hypertrophy and possibly prostate cancer.
It is clear that to intervene and improve a prostate disorder is necessary to combine an
activity anti: inflammatory, bacterial, tumor with a muscle relaxant component and antioxidant.
To this end, Cistiprost through the many activities, scientifically attributed to its
components (see below), involved in countering and combating the various factors
responsible for prostate and bladder disease, also contributing to a significant
improvement in quality of life of patients .
It 's especially important to highlighted that the individual components present in
CISTIPROST, have not caused, even during significantly prolonged recruitment, changes
in the hormone system, which instead are well known to other products anti-prostate.
CISTIPROST can also be taken together and in support to a drug therapy.
BIBLIOGRAPHY
Matthias Oelke, Martin C. Michel What do we really know about benign prostatic
hyperplasia and lower urinary tract symptoms in adult men? Hannover Medical School,
Germany e University of Amsterdam, World J Urol (2011) 29:141–142 DOI
10.1007/s00345-011-0664-5
Yallapu MM, Jaggi M, Chauhan SC. beta-Cyclodextrin-curcumin self-assembly enhances
curcumin delivery in prostate cancer cells. USA. Colloids Surf B Biointerfaces. 2010 Aug
1;79(1):113-25. Epub 2010 Apr 3.
Marie-He´le`ne Teiten, Franc¸ois Gaascht, Serge Eifes, Mario Dicato, Marc Diederich
Chemopreventive potential of curcumin in prostate cancer Luxembourg, Luxembourg
Genes Nutr (2010) 5:61–74 DOI 10.1007/s12263-009-0152-3
N Krzysztof Waliszewski, DSC, Blasco Gabriela, MSc Proprietà nutraceutiche del
licopene, Messico Salud Publica Mex vol. 52 n.3 Cuernavaca maggio/giugno 2010
Moon DO, Kang CH, Kim MO, Jeon YJ, Lee JD, Choi YH, Kim GY. Beta-lapachone
(LAPA) decreases cell viability and telomerase activity in leukemia cells: suppression of
telomerase activity by LAPA. Republic of Korea. J Med Food. 2010 Jun;13(3):481-8.
Daniella Bianchi-Frias, Funda Vakar-Lopez, Ilsa M. Coleman, Stephen R. Plymate, May J.
Reed, Peter S. Nelson The Effects of Aging on the Molecular and Cellular Composition of
the Prostate Microenvironment Washington, September 1, 2010
GUO Li-jun, TANG Yuan, GUO Chao-ming and ZHANG Xiang-hua Impact of primary
hypertension on hematuria of the patients with benign prostatic hyperplasia Peking
University, Gansu Province People Hospital, Lanzhou, Chin Med J 2010;123(9):1154-1157
Camila B. Piantino, Fernanda A. Salvadori, Pedro P. Ayres, Raphael B. Kato, Victor
Srougi, Katia R. Leite, Miguel Srougi An Evaluation of the Anti-neoplastic Activity of
Curcumin in Prostate Cancer Cell Lines Laboratory of Medical Investigation (CBP, FAS,
PPA, RBK, VS, KRL, MS), Sao Paulo, Brazil International Braz J Urol Vol. 35 (3): 354-361,
May - June, 2009
Lívia L. Corrêa1, Giovanna A. Balarini Lima, Helena B. de Melo Paiva, Cíntia M. dos
Santos Silva, Suzana A. Cavallieri, Luiz Carlos D. de Miranda, Mônica R. Gadelha
Prostate cancer and acromegaly Brasil Arq Bras Endocrinol Metab. 2009;53(8):963-8
Marion E. T. McMurdo1, Ishbel Argo, Gabby Phillips, Fergus Daly and Peter Davey
Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A
randomized controlled trial in older women School, University of Dundee, Scotland, UK
Journal of Antimicrobial Chemotherapy (2009) 63, 389–395
Wertz K. Lycopene effects contributing to prostate health DSM Nutritional Products Ltd.,
Basel, Switzerland Nutr Cancer 2009 Nov; 61(6):775-83
Chan R, Lok K, Woo J. Prostate cancer and vegetable consumption. Mol Nutr Food Res.
2009 Feb;53(2):201-16.
Andrzejewski T, Deeb D, Gao X, Danyluk A, Arbab AS, Dulchavsky SA, Gautam SC.
Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory
prostate cancer. Department of Surgery, Detroit, MI, USA. Oncol Res. 2008;17(6):257-67.
Eyong KO, Kumar PS, Kuete V, Folefoc GN, Nkengfack EA, Baskaran S. Semisynthesis
and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone
derivatives from lapachol. Indian Institute of Technology Madras, India. Bioorg Med Chem
Lett. 2008 Oct 15;18(20):5387-90. Epub 2008 Sep 17.
Lien YC, Kung HN, Lu KS, Jeng CJ, Chau YP. Involvement of endoplasmic reticulum
stress and activation of MAP kinases in beta-lapachone-induced human prostate cancer
cell apoptosis. Taiwan. Histol Histopathol. 2008 Nov;23(11):1299-308.
Thore Santel, Gabi Pflug, Nasr Y. A. Hemdan, et all. Curcumin Inhibits Glyoxalase 1—A
Possible Link to Its Anti-Inflammatory and Anti-Tumor Activity Institute of Biochemistry,
Germany Daniel Tome October 23, 2008
Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cancer Care
Research Centre Stirling, UK Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001321.
Ke-Hung Tsui et al. Curcumin Blocks the Activation of Androgen and Interlukin-6 on
Prostate-Specific Antigen Expression in Human Prostatic Carcinoma Cells Department of
Urology and the Molecular Image Center Taiwan, Republic of China.
Jepson RG, Craig JC. A systematic review of the evidence for cranberries and blueberries
in UTI prevention. University of Stirling, UK Mol Nutr Food Res. 2007 Jun;51(6):738-45.
Catherine C. Neto Cranberry and Its Phytochemicals: A Reviewof In Vitro Anticancer
Studies University of Massachusetts–Dartmouth J. Nutr. 137: 186S–193S, 2007.
Salman H, Bergman M, Djaldetti M, Bessler H. Lycopene affects proliferation and
apoptosis of four malignant cell lines. Tel-Aviv University, Ramat-Aviv, Israel.Biomed
Pharmacother. 2007 Jul;61(6):366-9. Epub 2007 Mar 19.
Sharmila Shankar and Rakesh K. Srivastava Involvement of Bcl-2 family members,
phosphatidylinositol 3-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)induced apoptosis in prostate cancer, University of texas Health Center, Tyler International
Journal of Oncology 30: 905-918, 2007
Kim SO, Kwon JI, Jeong YK, Kim ND, Choi YH, Lapacho tree (Tabebuia avallanedae) antiinfiammatory and anti-cancer activities. Dongeui University College of Oriental Medicine.
Biosci Biochem. 2007 Sep; 71(9): 2196-76 2007 Sep. 7
Liu Y, Black MA, Caron L, Camesano TA. Role of cranberry juice on molecular-scale
surface characteristics and adhesion behavior of Escherichia coli. Worcester Polytechnic
Institute Biotechnol Bioeng. 2006 Feb 5;93(2):297-305.
Edward H. Oswald Rapporto descritivo, analitico e delle attività del “Lapacho- Tabebuia”
da british Journal of Phytotherapy, vol. 3 n. 3, 1993/1994
Ammon HP, Safayhi H, Mack T, Sabieraj J. Mechanism of antiinflammatory actions of
curcumine and boswellic acids. Department of Pharmacology, Tübingen, FRG. J
Ethnopharmacol. 1993 Mar;38(2-3):113-9.
Oga S. and Sekino T: Toxicidade e atividade anti-inflamatoria de Tabebuia Avell. Lorentz
e Griesbach. Rev Fac Farm Bioquim S. Paulo 7, 47-53, 1969
How to use: 1-2 tablets per day, according to medical opinion, preferably at least one hour
before meals.
Contraindications: do not be carried over the recommended dosage of each ingredient.
Possible rare episodes of individual hypersensitivity.
Note for guidance: if the patients undergoing drug therapy is forced to stop the treatment
procedure, due to possible side effects of medication, individual
intolerance or temporary discontinuation of drug therapy, the
Cistiprost can be useful in continuing the control of homeostasis
of referee organs.
Read and follow the specific assessment of your doctor,before you start taking the
product.
N.B. All information regarding the activities of the various ingredients in Cistiprost, are
reflected in publications of University Institutes, international researchers and Various
Authors, available on the website of free access (www.pubmed.gov inserting into the
search engine the names of the individual components).
This summary has as its goal to brink back some of the possible benefits that the
components present in Cistispost can contribute to make.
PHARMACEUTICAL & BIO-NATURAL COMPANY
Registered at the Health Minister Registrar No. 1599
Registration at the Turin Court No. 2431/92 – Chamber of Commerce of Turin No. 0778545 – VAT Registration No. 06328630014
Headquarters: Via Garzigliana 8 – 10127 Turin Italy
Administr. Offices and Stocking Area: Via Beinette 8/D – 10127 Turin Italy – Phone + 39 011 6961244 – Fax + 39 011 6787072
e-mail address: [email protected] Website : www.europharma.it